Cobra Venom Factor (CVF)

Purity ≥85% (SDS-PAGE)Product introduction1. Induced complement deficiency animal model, CVF has been used for complement deficiency model preparation in various animals (mice, rats, guinea pigs, sheep, etc.). Or it can be used to treat various disease animal models to study the role of the complement system in the pathogenesis of disease. 2. Use CVF to bind to tumor-associated antigen monoclonal antibody to selectively kill and destroy tumors. CVF monoclonal antibody can promote the specific uptake of anti-tumor embryonic antigen antibodies by tumor cells, and different CVF monoclonal antibody conjugates have different cytotoxicity to human neuroblastoma. 3. Inhibiting the complement system to overcome xenograft-induced rejection and acute vascular rejection Multiple studies have shown that CVF can effectively inhibit ultra-acute rejection and prolong the survival time of the host. FunctionCobra Venom Factor (CVF), sometimes referred to as C3b(Cobra), is the non-toxic, complement activating component of cobra venom. 1-3 Like naturally occurring C3b, CVF forms a complex with complement components Factor B and Factor D. This CVFBbD convertase is capable of activating C3 in a wide variety of species via the alternative complement pathway. Unlike the naturally occurring convertase (C3bBbD), the C3b(Cobra)BbD convertase is Factor H resistant and is therefore not inactivated by Factor I or CR1. Given appropriate incubation time, CVF will convert nearly 100% of the C3 to C3 end products. Unlike CVF purified from the Naja naja haje species, CVF from Naja naja kaouthia activates the terminal pathway directly by forming a C5 convertase. 4,5 This depletes C5 in a manner analogous to that described above for C3. Levels of iC3b, C3a, SC5b-9, C5a and the Factor B cleavage product Bb are all extremely high in CVF treated sera. Specifications and Purity: ≥85% (SDS-PAGE), Active. Related Document: https://ald-pub-files.oss-cn-shanghai.aliyuncs.com/aladdinsci/pdp/sds/1/C501142-SCI_5e40bfb67de972e3c67c6ed009e0666b.pdf.